CompletedNot Applicable

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

United States130 participantsStarted 2014-07-22

Plain-language summary

This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer. Studying circulating tumor DNA from patients with head and neck or lung cancer in the laboratory may help doctors predict how well patients will respond to treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients older than 18 years age
✓. Diagnosis of advanced HNC (Stage III, IVA, IVB, IVC) or NSCLC (Stage IIA, IIB, IIIA, IIIB, IV) (patients with synchronous advanced HNC and NSCLC are eligible)
✓. ECOG performance status score of 0-3
✓. Life expectancy of 3 months or longer
✓. Patients able to provide a written informed consent prior to study entry

Exclusion criteria

✕. Prior chemotherapy or full course of radiotherapy for their present advanced HNC or NSCLC
✕. Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated basal or squamous cell carcinoma of skin
✕. Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study

What they're measuring

Predictive value of circulating tumor DNA for disease-free survival (DFS)/progression-free survival (PFS)

Timeframe: Up to 2 years

Trial details

NCT IDNCT02245100

SponsorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-14

View on ClinicalTrials.gov More Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma trials